A huge pharmaceuticals company pays a smaller rival millions not tosell a generic version of the drug giant’s product.Is it a smart business deal, or an illicit ploy to restraincompetition?
That’s one of the questions increasingly being asked as the powerfulbrand-name prescription drug industry fights to protect its profitsfrom smaller, generic drug makers vying to cash in by offering cheaperversions of popular drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
For questions call 1-877-256-2472 or contact us at [email protected]